Stifel Downgrades Celladon Corp (CLDN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
H.C. Wainwright Downgrades Celladon Corp (CLDN) to Neutral
April 28, 2015 7:48 AM EDTH.C. Wainwright downgraded Celladon Corp (NASDAQ: CLDN) from Buy to Neutral and removed its price target. This weekend Celladon announced that its Phase 2b CUPID 2 trial did not meet its primary and secondary endpoints.
"MYDICAR was deemed to be safe, but... More
Roth Capital Downgrades Celladon Corp (CLDN) to Neutral
April 27, 2015 7:19 AM EDTRoth Capital downgraded Celladon Corp (NASDAQ: CLDN) from Buy to Neutral with a price target of $2.00.
For an analyst ratings summary and ratings history on Celladon Corp click here. For more ratings news on Celladon Corp click here.
Shares of Celladon Corp closed at $13.68 yesterday.
... MoreWedbush Downgrades Celladon Corp (CLDN) to Neutral on Trial Failure; Slashes PT to $3
April 27, 2015 7:18 AM EDTWedbush downgraded Celladon Corp (NASDAQ: CLDN) from Outperform to Neutral with a price target of $3.00 (from $29.00) after the company announced Sunday that Mydicar failed to meet the primary and secondary endpoints in CUPID2.
Analyst David Nierengarten said they view further development of... More
Celladon's (CLDN) Phase 2b CUPID2 Trial of MYDICAR Missed Primary, Secondary Endpoints
April 27, 2015 6:34 AM EDTCelladon Corporation (Nasdaq: CLDN) today announced that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints. CUPID2 is a randomized, double-blind, placebo-controlled, multinational trial evaluating a single, one-time, intracoronary infusion of the cardiovascular gene therapy agent MYDICAR® (AAV1/SERCA2a) versus placebo added to a maximal, optimized heart failure drug and device regimen.
In the study, the primary endpoint comparison of MYDICAR to placebo resulted in a hazard ratio of 0.93 (0.53, 1.65 95%CI) (p=0.81),... More
